0000000000621479

AUTHOR

Di Gioacchino M.

0000-0002-9224-5886

showing 2 related works from this author

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

Autophagy

2012

Klionsky, Daniel J. et al.

autophagy assays[SDV]Life Sciences [q-bio]AutolysosomeAutophagosome maturationautophagosomeBioinformaticsstressChaperone-mediated autophagyModelsLC3MESH: Animalsguidelinesautolysosome autophagosome flux LC3 lysosome phagophore stress vacuoleSettore BIO/06 - Anatomia Comparata E CitologiaComputingMilieux_MISCELLANEOUSSettore BIO/17Autophagy databaseautolysosome3. Good healthddc:540lysosomeEnergy and redox metabolism Mitochondrial medicine [NCMLS 4]methods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIANeuroniMAP1LC3BHumanautophagygenetics [Autophagy]AutofagiaMESH: Autophagy*/genetics[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAutofagia; Neuroni; istologiaBiologyModels BiologicalLC3; autolysosome; autophagosome; flux; lysosome; phagophore; stress; vacuoleddc:570AutophagyAnimalsHumansAutophagy-Related Protein 7[SDV.BC] Life Sciences [q-bio]/Cellular BiologyBiological Assay/methodsMolecular BiologyBiologyAutophagy; guidelines; autophagy assaysistologiaphagophoreMESH: HumansAnimals; Biological Assay; Humans; Models Biological; AutophagyvacuoleAnimal[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH: Models BiologicalPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]Cell BiologyBiologicalAutophagy/geneticsfluxAutophagosome membraneAutophagy Protein 5Human medicineMESH: Biological Assay/methods*Neuroscienceautolysosome; autophagosome; flux; LC3; lysosome; phagophore; stress; vacuoleAutophagy
researchProduct